NAYA

8-K - INVO Fertility, Inc. (0001417926) (Filer)

8-K - INVO Fertility, Inc. (0001417926) (Filer)

10-K - INVO Fertility, Inc. (0001417926) (Filer)

SARASOTA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:NAYA), formerly known as NAYA Biosciences, Inc., a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics, today confirmed it will begin trading under the new symbol "IVF" at the market open on April 28, 2025. The CUSIP number for the Company's common stock will remain unchanged. The symbol change follows the Company's announcement on April 14, 2025, regarding the strategic decision to separate its fertility and oncology businesses into distinct operations. "Our new Nasdaq ticker symbol of ‘IVF' reflect

8-K - INVO Fertility, Inc. (0001417926) (Filer)

Public company to operate under new name and concentrate on building, acquiring and operating fertility clinics and the distribution of FDA-cleared INVOcell device Private company to operate as NAYA Therapeutics and focus on clinical development of bifunctional antibodies SARASOTA, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc. (the "Company") (NASDAQ:NAYA), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition, and operation of fertility clinics, today announced its decision to separate its fertility and oncology operations. This strategic decision to separ

8-K - NAYA Biosciences, Inc. (0001417926) (Filer)

NT 10-K - NAYA Biosciences, Inc. (0001417926) (Filer)

8-K - NAYA Biosciences, Inc. (0001417926) (Filer)

8-K - NAYA Biosciences, Inc. (0001417926) (Filer)

SARASOTA, Fla. and MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. ("NAYA") (NASDAQ:NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture ("IVC") fertility treatments, announced today that it will effect a 1-for-12 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on March 18, 2025. Commencing with the opening of trading on The Nasdaq Capital Market on March 18, 2025, the Company's common stock will trade on a post-split basis un

DEFR14A - NAYA Biosciences, Inc. (0001417926) (Filer)

8-K - NAYA Biosciences, Inc. (0001417926) (Filer)

S-8 - NAYA Biosciences, Inc. (0001417926) (Filer)

SARASOTA, Fla. and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. ("NAYA") (NASDAQ:NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture ("IVC") fertility treatments, proudly supports the U.S. President's recent executive order aimed at reducing the cost of IVF and expanding access to fertility services. The order directs the Domestic Policy Council to develop policy recommendations within 90 days to protect IVF access and significantly lower out-of-pocket expenses and health plan costs for

New board reflects company's added focus on oncology & autoimmune diseases SARASOTA, Fla. and MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences ("NAYA") (NASDAQ:NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, today announced that its board of directors has nominated five new candidates with extensive experience in in the biotechnology industry to be approved at the company shareholder meeting scheduled for March 10th, 2025. Laurent Audoly, PhD is the cofounder and CEO of PriveBio, a precision medicine company, and a professor and strategic advisor at the Institute for Experient

DEFA14A - NAYA Biosciences, Inc. (0001417926) (Filer)

DEF 14A - NAYA Biosciences, Inc. (0001417926) (Filer)

PRE 14A - NAYA Biosciences, Inc. (0001417926) (Filer)

8-K - NAYA Biosciences, Inc. (0001417926) (Filer)

424B4 - NAYA Biosciences, Inc. (0001417926) (Filer)

EFFECT - NAYA Biosciences, Inc. (0001417926) (Filer)

SARASOTA, Fla. and MIAMI, Jan. 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences ("NAYA") (NASDAQ:NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, today announced the pricing of a public offering of an aggregate of 13,615,171 units at a public offering price of $0.70 per unit. Each unit consists of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock. The warrants will have an exercise price of $0.70 per share, will be exercisable immediately upon issuance, and will expire on the five year anniversary of the original issuance

S-1/A - NAYA Biosciences, Inc. (0001417926) (Filer)

8-K - NAYA Biosciences, Inc. (0001417926) (Filer)